drugset / Trial / NCT02232607

Efficacy and Safety of Lacidipine in Chronic Stable Angina

NCT02232607

Phase 2 Completed 283 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study was to explore whether lacidipine at doses of 2 mg, 4 mg and 6 mg decreased the symptoms of angina, compared to placebo in patients with chronic stable angina

Timeline

Start
1998-04
Primary completion
1999-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacidipine Small molecule 2 mg
Subject Lacidipine Small molecule 4 mg
Subject Lacidipine Small molecule 6 mg

Indications

No indication recorded.